Predicted to enable several functions, including DNA binding activity; TFIID-class transcription factor complex binding activity; and promoter-specific chromatin binding activity. Predicted to contribute to 3' overhang single-stranded DNA endodeoxyribonuclease activity and DNA binding activity. Involved in cellular response to organic cyclic compound. Predicted to be located in chromosome, telomeric region and nucleus. Predicted to be part of ERCC4-ERCC1 complex and nucleotide-excision repair factor 1 complex. Human ortholog(s) of this gene implicated in Fanconi anemia complementation group Q; XFE progeroid syndrome; pancreatic cancer; polyneuropathy due to drug; and xeroderma pigmentosum (multiple). Orthologous to human ERCC4 (ERCC excision repair 4, endonuclease catalytic subunit); PARTICIPATES IN altered nucleotide excision repair pathway; nucleotide excision repair pathway; INTERACTS WITH 3-aminobenzamide; bisphenol A; C60 fullerene.
DNA repair endonuclease XPF; Ercc4 protein-like; excision repair cross-complementation group 4; excision repair cross-complementing rodent repair deficiency, complementation group 4; LOC304719; RGD1560340; similar to ERCC4_MOUSE
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERCC4 mRNA, epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in decreased expression of ERCC4 mRNA]
3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC4 mRNA], 3-aminobenzamide inhibits the reaction [Glucose results in increased expression of ERCC4 protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ERCC4 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERCC4 mRNA
[bisphenol A co-treated with Fulvestrant] results in decreased methylation of ERCC4 gene, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ERCC4 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERCC4 mRNA
[ERCC1 protein binds to ERCC4 protein] which results in decreased susceptibility to Cisplatin, DUSP6 inhibits the reaction [Cisplatin results in increased expression of ERCC4 mRNA]
Curcumin inhibits the reaction [Glucose results in increased expression of ERCC4 mRNA], Curcumin inhibits the reaction [Glucose results in increased expression of ERCC4 protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ERCC4 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERCC4 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ERCC4 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ERCC4 mRNA
[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of ERCC4 mRNA, epigallocatechin gallate inhibits the reaction [potassium chromate(VI) results in decreased expression of ERCC4 mRNA]
3-aminobenzamide inhibits the reaction [Streptozocin results in increased expression of ERCC4 mRNA], Curcumin inhibits the reaction [Streptozocin results in increased expression of ERCC4 mRNA]
trichostatin A inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of ERCC4 mRNA] more ...
in silico assessment of alteration of DNA-protein, protein-protein interactions and observed reduction of DNA repair capacity in the context of nucleotide excision repair pathway for SNP
